...initiative; and the Heads of Medicines Agencies (HMA) and EMA Joint Big Data Taskforce and DARWIN...

...of EMA’s top priorities for incorporating real-world data earlier in the regulatory process is establishing DARWIN...
...Big Data Taskforce. Together with the Heads of Medicines Agencies (HMA), EMA plans to launch DARWIN...
...World Interrogation Network) by 2023. "The regulator network needs to be data-driven." Peter Arlett, EMA DARWIN...

...behavioral health tracking platform to better manage population health. That same year, Sanofi launched its DARWIN...

...of an improvement in ACR20 at 12 weeks in the Phase IIb DARWIN 1 and DARWIN...
...Comparing JAK-1s Trial Population Dosage No. patients ACR20 at 12 weeks P-value Filgotinib Ph IIb DARWIN...
...twice daily 85 59% Not reported 100 mg twice daily 84 80% <0.001 Ph IIb DARWIN...

...statistically significant vs. placebo. In April, Galapagos announced 12-week efficacy data for the Phase IIb DARWIN...

...Final data from the double-blind, placebo-controlled, international Phase IIb DARWIN 2 trial in 283 patients with...

...and commercialize GLPG0634 for rheumatoid arthritis (RA) and CD. Upon completion of the Phase II DARWIN...

...Final data from the double-blind, international Phase IIb DARWIN 1 trial in 594 patients with moderate...

...Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported 24-week data from the Phase IIb DARWIN 1 trial of filgotinib...
...Disease Activity Score using 28 joint counts (DAS28). Galapagos expects data from the Phase IIb DARWIN...

...said Muijrers. In July, Galapagos is slated to report full results from the Phase IIb DARWIN...
...about safety." In August, Galapagos is slated to report additional data from the Phase IIb DARWIN...
...NYSE:ABBV) Filgotinib (GLPG0634) Rheumatoid arthritis (RA) Top-line Ph IIb DARWIN 1 data; Top-line Ph IIb DARWIN...